Agonist-specific down regulation of mu-opioid receptors: Different cellular pathways are activated by different opioid agonists.
Opioid agonists are known to induce down regulation of opioid receptors through the classical pathway that involves phosphorylation, clathrin-dependent endocytosis and lysosomal/endosomal degradation of the internalized receptors. As expected, exposure of mu-opioid receptor (MOR)-transfected HEK-293 cells to either DAMGO (a specific mu-opioid agonist) or etorphine (a wide spectrum opioid agonist) resulted in down regulation of the receptors that was blocked by the kinase inhibitor staurosporine, by hypertonic sucrose and by the lysosomal and proteasomal inhibitors chloroquine and lactacystin. High concentration of etorphine, but not of DAMGO, induced an additional process of down regulation that was resistant to staurosporine, to hypertonic sucrose and to chloroquine-lactacystin. Etorphine, but not DAMGO, also induced down regulation of mu-opioid receptors in isolated membranes of HEK cells. This membrane-delimited down regulation was blocked by selective inhibitors of protease enzymes, suggesting the involvement of membranous serine- and amino-peptidases. This membranous down regulation of opioid receptors was dependent on the concentration of etorphine and was blocked by the opioid antagonist naloxone. Etorphine induced similar down regulation in membranes of HEK-293 cells transfected with delta-opioid receptors (DOR) as well in membranes of cells that endogenously express opioid receptors. This agonist-specific membrane-delimited regulatory process appears to be physiologically relevant and should be taken into account when studying long term effects of opioid drugs.
Binyaminy
Binyamin
B
The Mauerberger Chair in Neuropharmacology, Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel.
Gafni
Mikhal
M
Shapira
Ma'anit
M
Sarne
Yosef
Y
D000626:Aminopeptidases / Q000378:metabolism; D000701:Analgesics, Opioid / Q000819:agonists*; D002448:Cell Adhesion; D002966:Clathrin / Q000494:pharmacology; D018076:DNA, Complementary / Q000096:biosynthesis / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000494:pharmacology; D005048:Etorphine / Q000494:pharmacology; D006801:Humans; D008247:Lysosomes / Q000187:drug effects / Q000502:physiology; D008566:Membranes / Q000187:drug effects / Q000378:metabolism; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D010770:Phosphotransferases / Q000378:metabolism; D011480:Protease Inhibitors / Q000494:pharmacology; D017450:Receptors, Opioid, mu / Q000819:agonists*; D012697:Serine Endopeptidases / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*
D000701:Analgesics, Opioid; D002966:Clathrin; D018076:DNA, Complementary; D009292:Narcotic Antagonists; D011480:Protease Inhibitors; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D009270:Naloxone; D005048:Etorphine; D010770:Phosphotransferases; D000626:Aminopeptidases; D012697:Serine Endopeptidases